A Recent U.S. Food and Drug Administration (FDA) approval of suzetrigine (JOURNAVX®) is a breakthrough in acute-pain management. “In the pain treatment world, it is exciting to see the first of a new class of non-opioid pain relievers,” says Annabelle Hood, PharmD, BCACP, Cleveland Clinic pharmacy specialist in pain management.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Arthritis Advisor
Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
